To determine any advantages in patient survival, the immunotherapy cases were compared with the control group consisting of patients in better condition (under 76 years old, STR/GTR cases) but with similar patient background, age, tumor side, preoperative KPS, EOR, p53 status, and the use of proton therapy, as shown in Supplementary Table 2. Here, TP53 is linked to neoplasm.